Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[64Cu]Cu-Dimer_D
- Development stage
- Preclinical
- Lead developer
- University of Virginia
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[64Cu]Cu-Dimer_D is a preclinical, research-stage radiopharmaceutical diagnostic agent developed by Washington University School of Medicine and the University of Virginia for positron emission tomography (PET) imaging of multiple myeloma. It consists of a dimeric-inverso peptide targeting CD38 (ADP-ribosyl cyclase 1) conjugated to a DIAMSAR chelator and radiolabeled with the positron-emitting isotope copper-64 (64Cu). The dimeric structure, composed of two D-amino acid-based monomeric peptide units (Monomer_D) linked via a PEG4 spacer, provides enhanced binding affinity and cellular uptake in CD38-overexpressing multiple myeloma cells (such as MOLP2) through avidity-driven engagement compared to its monomeric counterpart. In preclinical mouse models of multiple myeloma, [64Cu]Cu-Dimer_D demonstrated high serum stability, intense tumor-specific uptake, and clear visualization of skeletal lesions on PET/CT scans.
- Other names
- [64Cu]Cu-Dimer-D[⁶⁴Cu]Cu-Dimer_DCu-Dimer_D
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on [64Cu]Cu-Dimer_D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [64Cu]Cu-Dimer_D.